RecruitingPhase 2NCT07501702
Neuromuscular
Myasthenia Gravis
Also known as MG, autoimmune neuromuscular junction disorder, AChR antibody positive MG
Myasthenia gravis is an autoimmune disease in which antibodies attack proteins at the neuromuscular junction - most commonly the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). This disrupts nerve-to-muscle signaling, causin
95
studies recruiting now
as of 7 Sept 2026
352
studies registered in total
as of 7 Sept 2026
10
countries with a recruiting site
as of 7 Sept 2026
15 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 4NCT07072988
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
RecruitingPhase 1NCT07215650
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
RecruitingPhase 3NCT07647510
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
RecruitingPhase 2NCT06987539
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 95 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Myasthenia Gravis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: MG Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Myasthenia Gravis
Myasthenia gravis is an autoimmune disease in which antibodies attack proteins at the neuromuscular junction - most commonly the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). This disrupts nerve-to-muscle signaling, causing fluctuating muscle weakness that worsens with activity and improves with rest. It is highly treatable with cholinesterase inhibitors, immunosuppressants, and newer complement inhibitors like eculizumab.
Common clinical features
Muscle weaknessFatigable weakness of skeletal musclesAcetylcholine receptor antibody positivityFatiguePtosisDiplopiaDysphagiaThymus hyperplasia
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
14 approved treatments and 36 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Neostigmine Methylsulfate (Bloxiverz)Approved: Pralidoxime Chloride (Contrathion)Approved: Pyridostigmine Bromide (Mestinon)Approved: Guanidine Hydrochloride (Guanidine hydrochloride)Approved: Amifampridine (Ruzurgi)Approved: NeostigmineApproved: Amifampridine Phosphate (Amifampridine serb)Approved: AmbenoniumApproved: EdrophoniumApproved: Rozanolixizumab (Rystiggo)Approved: Zilucoplan Sodium (Zilbrysq)Approved: PyridostigmineApproved: NipocalimabApproved: Efgartigimod Alfa (Efgartigimod alfa component of vyvgart hytrulo)
Phase 3Ravulizumab (Ultomiris)
Phase 3Satralizumab (Enspryng)
Phase 3Batoclimab
Phase 3Sodium Chloride (Aqsia (balanced salt soln))
Phase 3Inebilizumab (Uplizna)
Phase 3Mycophenolate Mofetil (Arzip)
Phase 3Rituximab (Blitzima)
Phase 3Zilucoplan
+ 28 more in development
Before you apply
Things trial teams commonly ask about for Myasthenia Gravis. Not eligibility rules; those are set by each study.
- Antibody status (AChR-positive, MuSK-positive, or seronegative) is the most critical eligibility factor
- MGFA clinical classification (Class I through V) and QMG score are standard trial entry criteria
- Thymoma status and prior thymectomy are required safety screens in most trials
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).